MISONIX INC. overview

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Misonix, Inc. (NasdaqGS: MSON) to Bioventus Inc. (Nasdaq: BVS). Under the terms of the proposed transaction, shareholders of Misonix may elect to receive either (i) 1.6839 shares of Bioventus class A common stock or (ii) $28.00 in cash, without interest, for each share of Misonix that they own. KSF is seeking to determine whether this...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Misonix, Inc. - MSON PR Newswire NEW YORK, July 31, 2021 NEW YORK , July 31, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City , is investigating Misonix, Inc. ("MSON" or the "Company") ( MSON ) relating to...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Misonix, Inc. PR Newswire NEW YORK, July 30, 2021 NEW YORK , July 30, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Misonix, Inc. ("Misonix" or the "Company") (NASDAQ: MSON) in connection with the proposed cash-and-stock acquisition of the Company by Bioventus Inc. ("Bioventus") (NASDAQ: BVS). Under the terms of the merger agreement, Misonix shareholders...

Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Misonix, Inc. (NASDAQ: MSON) to Bioventus Inc. is fair to Misonix shareholders. Under the terms of the agreement, Misonix stockholders may elect to receive either (i) 1.6839 shares of Bioventus class A common stock or (ii) $28.00 in cash, without interest, for each share of Misonix common stock they hold, subject to proration. Halper Sadeh encourages Misonix shareholders to click here to learn more about...

CryoLife and Misonix Enter Into Distribution Agreement for NeoPatch CryoLife Will Supply NeoPatch, a Chorioamniotic Membrane Tissue, to Misonix PR Newswire ATLANTA, Dec. 19, 2019 ATLANTA , Dec. 19, 2019 /PRNewswire/ -- CryoLife, Inc. ("CryoLife"; NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has entered into an agreement whereby Misonix (NASDAQ: MSON) will have exclusive US commercialization rights for CryoLife's NeoPatch product to...

NEW YORK, NY / ACCESSWIRE / February 6, 2018 / Misonix, Inc. (NASDAQ: MSON ) will be discussing their earnings results in their Q2 Earnings Call to be held on February 6, 2018 at 4:30 PM Eastern Time. To listen to the event live or access a replay of the call - visit https://www.investornetwork.com/company/22243 . To receive updates for this company you can register by emailing [email protected] or by clicking get investment info from the company's profile. About Investor Network Investor...

Misonix Reports First Quarter Fiscal Year 2018 Financial Results PR Newswire FARMINGDALE, N.Y., Nov. 7, 2017 FARMINGDALE, N.Y. , Nov. 7, 2017 /PRNewswire/ -- Misonix, Inc. (Nasdaq: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, announced today financial results for the first quarter of fiscal year 2018, ended September 30, 2017 . Financial Highlights for the First Quarter: Revenue for the first quarter of fiscal year 2018 was $7.3...